The United Kingdom and the United States have forged a key trade agreement that will keep zero duties on UK pharmaceutical exports being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has committed to increase expenditure on drugs through the National Health Service (NHS). This pledge ensures that import taxes on these key exports will be held at nothing for a timeframe of 36 months.
This agreement follows previous statements to significantly raise import taxes on branded pharmaceutical products, with figures floated as high as one hundred percent.
"This agreement with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to transatlantic medicine commerce," an announcement said.
Economic Impact
Pharmaceuticals are one of the the United Kingdom's most significant export categories to the US, which is clearly the primary destination for leading companies like GSK and AstraZeneca.
Statistics show that in the 12 months leading up to the third quarter, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This value made up 17.4% of British export trade in that period.
"This guarantee safeguards employment, boosts capital expenditure and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary commented.
Key UK Commitments
The pact entails several key commitments from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall NHS spending on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to control costs will be capped at fifteen percent. Last year, rebates exceeded 20%.
Industry Background
This agreement comes amid a protracted row between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
This friction were heightened by assertions that US patients were paying a premium for the same drugs than consumers in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the last ten years.
